Thiamine deficiency as a possible cofactor causing cognitive dysfunction in a patient with end-stage gastric cancer .
Journal
International journal of clinical pharmacology and therapeutics
ISSN: 0946-1965
Titre abrégé: Int J Clin Pharmacol Ther
Pays: Germany
ID NLM: 9423309
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
accepted:
17
07
2019
pubmed:
25
6
2019
medline:
6
8
2019
entrez:
25
6
2019
Statut:
ppublish
Résumé
We describe a case of a patient treated for cognitive dysfunction (CD) with suspected thiamine deficiency (TD). A 74-year-old man with gastric cancer presented with grade 3 diarrhea and grade 1 anorexia. He had been receiving trastuzumab plus tegafur (a chemotherapeutic fluorouracil prodrug), gimeracil, and oteracil (S-1) and oxaliplatin. On admission, cognitive function was assessed with the Hasegawa's Dementia Scale (HDS-R) because he had impaired short-term memory. His thiamine levels increased from 22 to 109 ng/mL after administration of 75 mg of thiamine. Furthermore, the patient's HDS-R score improved from 9 to 22, and cognitive and memory functions improved. TD should be considered in older CD patients receiving oral chemotherapy agents including fluorouracil.
Identifiants
pubmed: 31232276
pii: 185272
doi: 10.5414/CP203384
doi:
Types de publication
Case Reports
Journal Article
Langues
eng